Exelixis Inc
NASDAQ:EXEL
Exelixis Inc
Exelixis Inc., founded in 1994, embarked on its journey in the biotech sector with a sharp focus on genomics and drug discovery. This San Francisco-based biopharmaceutical company has firmly imprinted its name within the oncology space, thanks to its innovative research and development endeavors. One of the company's flagship achievements is the development and commercialization of cabozantinib, a compound used to treat various types of cancer. Marketed under the brand names like Cabometyx and Cometriq, cabozantinib targets tumor growth and angiogenesis, the process through which tumors develop their own blood supply. By honing in on these therapeutic areas, Exelixis capitalizes on its robust pipeline and partnerships with other healthcare stakeholders, thus carving out a niche in precision medicine.
The company's business model primarily revolves around the development, commercialization, and strategic licensing of its drug candidates. Through extensive research and collaborative efforts, Exelixis not only advances its own proprietary medications but also licenses out their discoveries to maximize outreach and revenue potential. Revenue streams are generated through product sales, developmental milestones, and royalties, with significant investments poured back into research to fuel future innovation. In the intricate dance of biotech, Exelixis thrives on balancing the risk of high research costs with the lucrative potential of breakthrough cancer treatments, demonstrating a conscious strategy of leveraging scientific expertise into a commercially viable portfolio.
Exelixis Inc., founded in 1994, embarked on its journey in the biotech sector with a sharp focus on genomics and drug discovery. This San Francisco-based biopharmaceutical company has firmly imprinted its name within the oncology space, thanks to its innovative research and development endeavors. One of the company's flagship achievements is the development and commercialization of cabozantinib, a compound used to treat various types of cancer. Marketed under the brand names like Cabometyx and Cometriq, cabozantinib targets tumor growth and angiogenesis, the process through which tumors develop their own blood supply. By honing in on these therapeutic areas, Exelixis capitalizes on its robust pipeline and partnerships with other healthcare stakeholders, thus carving out a niche in precision medicine.
The company's business model primarily revolves around the development, commercialization, and strategic licensing of its drug candidates. Through extensive research and collaborative efforts, Exelixis not only advances its own proprietary medications but also licenses out their discoveries to maximize outreach and revenue potential. Revenue streams are generated through product sales, developmental milestones, and royalties, with significant investments poured back into research to fuel future innovation. In the intricate dance of biotech, Exelixis thrives on balancing the risk of high research costs with the lucrative potential of breakthrough cancer treatments, demonstrating a conscious strategy of leveraging scientific expertise into a commercially viable portfolio.
Strong Revenue Growth: Exelixis reported 2025 U.S. cabozantinib franchise net product revenue of $2.12 billion, up 17% year-over-year. Q4 U.S. cabo franchise net product revenues grew 6% YoY to $547 million.
Neuroendocrine Tumor Success: CABOMETYX net product revenue from neuroendocrine tumor indications exceeded $100 million in 2025, establishing it as the market leader in the oral segment.
Zanzalintinib Pipeline Progress: The NDA for the zanza/atezo combination in third-line+ colorectal cancer was accepted, with a PDUFA action date set for December 3, 2026. Multiple pivotal trials for zanza are ongoing or planned.
Share Repurchases: The company repurchased $954 million of stock in 2025, retiring about 24 million shares, with $590 million remaining under the current repurchase authorization.
2026 Guidance and Investments: Exelixis provided financial guidance for 2026 and expects continued investment in its pipeline, business development, and commercial infrastructure, including a newly expanded GI sales team to support near-term launches.
